Injection-site adverse experiences between Gardasil and control arms
| Trial | Gardasil | Control | Difference | Source |
| V501-012 | 87.9% | 78.6% (with AAHS) | 9.3% | CSR p.33 |
| V501-013 | 88.0% | 79.8% (with AAHS) | 8.2% | CSR p.13 |
| V501-015* | 84.4% | 77.9% (with AAHS) | 6.5% | Publication table 4 |
| V501-019 | 76.7% | 64.2% (with AAHS) | 12.5% | CSR p.566 |
| V501-020 | 60.1% | 53.7% (with AAHS) | 6.4% | CSR p.348 |
| V501-018 | 75.3% | 50.0% (without AAHS) | 25.3% | CSR p.33 |
*The CSR for V501-015 reports injection-site adverse experiences as 8.8% (qHPV) versus 7.6% (control), but these figures are likely an underestimate as injection-site adverse experiences were only collected for participants in the Non-Serious Adverse Experience Substudy, and data for this subpopulation were reported in the publication but not CSR.
AAHS, amorphous aluminium hydroxyphosphate sulfate; CSR, clinical study reports.